Portfolio Optimization Across 4 Areas and Investment in Priority Areas
First written in FY2016. 22 of 36 entries say "Advanced", first in FY2017. Latest entry: FY2026.
Nagase & moved to the "Worse" side of this theme in 2026, 2 years after the typical company in this theme (2024).
22 other companies' latest entry also says "Reframed".
- FY2026ReframedAnnual report
「Under Walk the Talk 2028, we established three areas: “Growth,” responsible for portfolio realignment and pursuing greater efficiency; “Focus,” aimed at further strengthening the competitive advantages of our products; and “Challenge,” where we will lay the groundwork for future sources of earnings.」
For the next plan, the functional-axis portfolio of ACE 2.0—“Foundation,” “Priority,” “Development” and “Improvement”—was reorganized into three areas: “Growth,” “Focus” and “Challenge.” - FY2026-H1Additional recognition of losses related to businesses exited in the pastAnnual report
「During the interim consolidated accounting period, the provision for losses on business withdrawals increased by ¥1,672 million, reducing interim profit before income taxes and other adjustments by ¥1,625 million.」
For the thin glass substrate processing business in China, whose withdrawal was decided in fiscal 2020, an additional provision was recognized following new information on soil treatment costs and other matters. - FY2026-H1AdvancedAnnual report
「Following a new equity investment to establish NAGASE WAHLEE INDIA PRIVATE LIMITED, it was included within the scope of consolidation. Following the acquisition of equity interests, Seikhem Japan Holdings合同会社, Seikhem Japan合同会社 and 無錫三開高純化工有限公司, 3 companies in total, were included within the scope of consolidation.」
Investment in priority areas and portfolio replacement progressed through the new equity investment in India and the acquisition of 3 companies in the Electronics & Energy field. - FY2025AdvancedAnnual report
「The 4 quadrants had previously been classified by business axis, but in fiscal 2023 we reorganized the business portfolio by functional axis and clarified the priority fields in each area to make future growth more certain.」
The company reorganized portfolio management across 4 areas by functional axes such as trading, manufacturing and research and development. It clarified food, semiconductors and life sciences as priority fields and advanced concrete measures, including withdrawal from the Color Former business in the United States and efficiency improvements in Japan, expanded semiconductor production capacity, and the construction of a new TMAH recovery and regeneration plant. - FY2025-H1AdvancedAnnual report
「The Color Former business reduced losses by stopping production in the United States and restructuring and streamlining operations at its manufacturing base in Japan.」
As concrete measures for portfolio optimization and business replacement, the company proceeded with the cessation of production in the United States and the restructuring and streamlining of its manufacturing base in Japan, reducing losses in the Color Former business. - FY2024-Q3AdvancedAnnual report
「From the beginning of the third quarter of the consolidated fiscal year under review, the former 11 business divisions were reorganized and consolidated into 7 business divisions to achieve efficient business operations through an expanded organizational scale and enhanced functions.」
The company consolidated 11 business divisions into 7 to expand its organizational scale and enhance its functions. This represents concrete progress in improving the efficiency of business classifications and segment operations. - FY2024-Q1AdvancedAnnual report
「Flavor Tec - Aromas de Frutas Ltda (as an equity interest was acquired on 28 June 2023); Fruttini Sucos de Frutas Ltda (as an equity interest was acquired on 28 June 2023)」
Regarding portfolio optimization and investment in priority areas, 2 fruit and food-related companies were added to the scope of consolidation through the acquisition of equity interests. - FY2023AdvancedAnnual report
「We built a plant in Salt Lake City, Utah, as a new base for the contract manufacturing business for sports nutrition products and commenced production.」
In the food-related business, a priority area, the company built a new plant in Utah, United States, and progressed to the start of production. - FY2023-Q3AdvancedAnnual report
「By segment, profit increased in the Lifestyle-related segment, driven by the Prinova Group, while the Functional Materials and Mobility segments remained strong. Meanwhile, profit declined in the Processing Materials and Electronics & Energy segments.」
The Lifestyle-related, Functional Materials and Mobility segments, which include priority areas, posted higher profit or remained strong, while profit declined in the Processing Materials and Electronics & Energy segments. - FY2023-Q1AdvancedAnnual report
「The Group's performance remained strong, supported by growth in the food-related and semiconductor-related businesses, which are priority areas under the medium-term management plan, as well as an upside impact on profit from the weaker yen.」
The company states that growth in the food-related and semiconductor-related businesses, which are priority areas under the medium-term management plan, contributed to results in the first quarter under review. - FY2022AdvancedAnnual report
「In fiscal 2021, as described above, we secured capital by withdrawing from some businesses in the Improvement area and promoted capital investment in priority areas. However, we recognize that business replacement has been insufficient, and in fiscal 2022 we will consider company-wide business replacement led by the corporate headquarters.」
The company secured capital by withdrawing from unprofitable businesses and selling subsidiaries, and invested capital in priority areas. It plans to consider company-wide business replacement in fiscal 2022. - FY2022-Q3AdvancedAnnual report
「During the third quarter of the consolidated fiscal year under review, The Ingredient House, LLC and Lakeshore Technologies, LLC were included within the scope of consolidation following the acquisition of equity interests.」
The company acquired 2 companies in the Lifestyle-related segment, expanding its business base in the priority area. - FY2022-Q1AdvancedAnnual report
「From the first quarter of the consolidated fiscal year under review, the segment name was changed from the former Electronics segment to the Electronics & Energy segment, and from the Mobility & Energy segment to the Mobility segment, respectively, together with the following changes to the business classifications.」
To promote new business development, the Energy Business Office and the Next-Generation Information and Communications Project Team were integrated to establish the Information and Communications & Energy Business Office. In addition, the Fluorine business was transferred to the Electronics & Energy segment to expand market share and improve synergies. - FY2021RaisedAnnual report
「To further accelerate the shift of resources, we will secure 10% of company-wide invested capital and reinvest it in the Priority and Growth areas.」
While continuing to manage the portfolio across 4 areas, the company has newly presented a quantitative resource allocation policy to reinvest 10% of company-wide invested capital in the Priority and Growth areas. - FY2021-Q3AdvancedAnnual report
「Senko Nagase Logistics㈱ (changed from a consolidated subsidiary to an equity-method affiliate following the sale of shares on 1 December 2020)」
As part of portfolio optimization, the company changed Senko Nagase Logistics㈱ from a consolidated subsidiary to an equity-method affiliate through the sale of its shares. - FY2021-Q2AdvancedAnnual report
「At a meeting of the Board of Directors held on 28 August 2020, we resolved to transfer all shares held in our consolidated subsidiary Nagase Pharmaceutical株式会社. On 31 August of the same year, we entered into a share transfer agreement with Shionogi Pharma株式会社, a wholly owned subsidiary of Shionogi & Co.,Ltd., and completed the transfer on 1 October of the same year.」
As concrete progress in portfolio optimization, the company transferred all shares in Nagase Pharmaceutical株式会社 to Shionogi Pharma株式会社 and completed the transaction on 1 October 2020. The stated reasons for the transfer were the business restructuring of Nagase Pharmaceutical株式会社 and growth with the acquiring party. - FY2021-Q1AdvancedAnnual report
「In the Lifestyle-related business, domestic sales declined due to lower demand resulting from the impact of COVID-19 and other factors. However, overseas sales increased because sales from the Prinova Group, acquired in the second quarter of the previous consolidated fiscal year, were added, resulting in a substantial overall increase in sales.」
In the Lifestyle-related business, a priority area, the increase in overseas sales following the acquisition of the Prinova Group and the expansion of the food ingredients business built around the group were reflected in the results. - FY2020-Q3AdvancedAnnual report
「Sales from the newly acquired Prinova Group were added in the second quarter of the consolidated fiscal year under review, resulting in a substantial increase in overseas sales.」
In the Lifestyle-related business, a priority area, the addition of sales following the acquisition of Prinova made the expansion of overseas sales tangible. - FY2020-Q2AdvancedAnnual report
「We position Prinova as a strategic platform for expanding the food ingredients business in Europe and the United States. Together with the food ingredients business of Hayashibara株式会社, our wholly owned consolidated subsidiary, we will expand the NAGASE Group's presence in Japan and Asia, the Americas and Europe.」
In line with the policy of making Life & Healthcare and the Americas priority areas and regions, the company acquired Prinova as a strategic platform for expanding its food ingredients business in Europe and the United States. - FY2020-Q1AdvancedAnnual report
「During the first quarter of the consolidated fiscal year under review, 3D Glass Solutions, Inc. was included within the scope of equity-method accounting following the acquisition of an equity interest.」
3D Glass Solutions, Inc., in which the company invested in FY2019, progressed to being treated as an equity-method affiliate. - FY2019AdvancedAnnual report
「During the fiscal year under review, in the Life & Healthcare field, a priority area, we began construction of a new plant producing pullulan, a natural polysaccharide, and various enzymes, with the aim of increasing production capacity in anticipation of future demand growth under our long-term partnership agreement with Lonza of Switzerland. We also decided to establish a Food Business Strategy Office to develop strategies for and expand the food ingredients market. In the Electronics field, also a priority area, we invested in 3D Glass Solutions to develop high-frequency products compatible with next-generation communications standards and expand the semiconductor business.」
In Life & Healthcare, the company began construction of a new plant and established a Food Business Strategy Office; in Electronics, it invested in 3D Glass Solutions. - FY2019-Q2RestatedAnnual report
「As key initiatives to achieve a transformation in our earnings structure, we have identified portfolio optimization and the expansion and strengthening of our earnings base. As key initiatives to achieve a transformation in our corporate culture, we have identified thorough adoption of the appropriate mindset and the strengthening of our management platform.」
The company has reaffirmed the key initiatives of ACE-2020, including portfolio optimization and the expansion and strengthening of its earnings base. - FY2019-Q1AdvancedAnnual report
「In the Electronics segment, following the establishment of Xenomax Japan株式会社, the company has included it within the scope of equity-method accounting from the first quarter of the consolidated fiscal year under review.」
Xenomax Japan株式会社, established in FY2018, progressed to being treated as an equity-method affiliate from April 2018. - FY2019-Q1RestatedAnnual report
「As key initiatives to achieve a transformation in our earnings structure, we have identified portfolio optimization and the expansion and strengthening of our earnings base. As key initiatives to achieve a transformation in our corporate culture, we have identified thorough adoption of the appropriate mindset and the strengthening of our management platform.」
The company has reaffirmed the key initiatives of ACE-2020, including portfolio optimization and the expansion and strengthening of its earnings base. - FY2018AdvancedAnnual report
「During the fiscal year under review, in the Life & Healthcare field, a priority area, we opened a new business location in Europe to expand the cosmetics business and decided to invest in PeptiStar株式会社, a venture company with next-generation drug discovery technologies. In the Electronics field, also a priority area, we established Xenomax Japan株式会社 in April 2018 as a joint venture with TOYOBO CO.,LTD. to produce and sell highly heat-resistant polyimide films in response to demand in the flexible display market, and invested in Kyulux株式会社, a venture company with next-generation organic EL technologies.」
In the priority areas, the company made several concrete investments and advanced commercialization, including opening a European base, investing in PeptiStar株式会社 and Kyulux株式会社, and establishing Xenomax Japan株式会社. - FY2018-Q3RestatedAnnual report
「As key initiatives to achieve a transformation in our earnings structure, we have identified portfolio optimization and the expansion and strengthening of our earnings base. As key initiatives to achieve a transformation in our corporate culture, we have identified thorough adoption of the appropriate mindset and the strengthening of our management platform.」
The company has reaffirmed the key initiatives of ACE-2020, including portfolio optimization and the expansion and strengthening of its earnings base. - FY2018-Q2RestatedAnnual report
「As key initiatives to achieve a transformation in our earnings structure, we have identified portfolio optimization and the expansion and strengthening of our earnings base. As key initiatives to achieve a transformation in our corporate culture, we have identified thorough adoption of the appropriate mindset and the strengthening of our management platform.」
The company has reaffirmed the key initiatives of ACE-2020, including portfolio optimization and the expansion and strengthening of its earnings base. - FY2018-Q1AdvancedAnnual report
「In the Electronics segment, following the decision to withdraw from the thin-glass processing business in Taiwan, we reduced the carrying amount of the assets used in that business to their recoverable amount. The impairment loss recognized was ¥220 million for the first quarter of the consolidated fiscal year under review.」
As part of portfolio optimization, the company decided to withdraw from the thin-glass processing business in Taiwan and recognized an impairment loss of ¥220 million on business-use assets. - FY2017AdvancedAnnual report
「During the fiscal year under review, in the Life & Healthcare field, a priority area, we expanded production facilities for Treha®, a functional carbohydrate, and expanded the manufacturing building for highly potent injectable products to increase production capacity. In the Electronics field, also a priority area, we acquired shares in Inkron Ltd. to strengthen the display, touchscreen and wearable businesses and sought to strengthen the partnership.」
In the priority areas, the company expanded Treha production facilities, expanded the manufacturing building for highly potent injectable products, and acquired shares in Inkron Ltd. - FY2017-Q3RestatedAnnual report
「As key initiatives to achieve a transformation in our earnings structure, we have identified portfolio optimization and the expansion and strengthening of our earnings base. As key initiatives to achieve a transformation in our corporate culture, we have identified thorough adoption of the appropriate mindset and the strengthening of our management platform.」
The company has reaffirmed the key initiatives of ACE-2020, including portfolio optimization and the expansion and strengthening of its earnings base. - FY2017-Q2RestatedAnnual report
「As key initiatives to achieve a transformation in our earnings structure, we have identified portfolio optimization and the expansion and strengthening of our earnings base. As key initiatives to achieve a transformation in our corporate culture, we have identified thorough adoption of the appropriate mindset and the strengthening of our management platform.」
The company has reaffirmed the key initiatives of ACE-2020, including portfolio optimization and the expansion and strengthening of its earnings base. - FY2017-Q1RestatedAnnual report
「As key initiatives to achieve a transformation in our earnings structure, we have identified portfolio optimization and the expansion and strengthening of our earnings base. As key initiatives to achieve a transformation in our corporate culture, we have identified thorough adoption of the appropriate mindset and the strengthening of our management platform.」
The company has reaffirmed the key initiatives of ACE-2020, including portfolio optimization. This quarterly report does not reiterate the allocation ratio of 35% or more of growth investment to priority areas. - FY2016First statedAnnual report
「We classified our businesses into 4 areas: Growth, Priority, Foundation and Improvement, and aim to expand the business by implementing strategies suited to each area. We have set the allocation ratio for growth investment to priority areas at 35% or more. Priority areas: Life & Healthcare and Electronics」
The company divided its businesses into 4 categories and designated Life & Healthcare and Electronics as priority areas.